In Events

San Diego, CA / May 18, 2009 /
Dr. Kenneth Kim, CEO of West Coast Clinical Trials (WCCT) presented a poster at the International Conference of the American Thoracic Society entitled, “Effect of Adjustable-Dose (AD) Budesonide/Formoterol Pressurized Metered-Dose Inhaler (pMDI), Fixed-Dose (FD) Budesonide/Formoterol pMDI, and FD Fluticasone/Salmeterol Dry Powder Inhaler (DPI)  on Predose FEF 25%-75%” .  For additional information regarding this study, please contact AstraZeneca.

About West Coast Clinical Trials, LLC

WCCT is an independent early phase clinical CRO with a 120-bed phase I facility with 10 telemetry equipped beds located in southern California. WCCT has a unique focus on Ethno-bridging studies along with extensive experience with healthy volunteer and specialty trials (allergy, asthma, infectious disease, pediatric, renal and vaccines). For more information, visit our Web site at
https://sponsor.wcct.com.

_____________________

Contact:

West Coast Clinical Trials
5630 Cerritos Ave.
Cypress, CA 90630 USA
Phone: (714) 252-0700
E-mail: mgr@wcctrials.com

Start typing and press Enter to search